Dr. Holger Müller

Dr. Holger Müller

Dr. Holger Müller

Vice President, Health Advances

Holger joined Health Advances in 2019. He is part of Health Advances’ biopharma practice. Holger applies his deep expertise in commercializing scientific innovations in product development strategy, product positioning, and field force optimization across a wide range of technologies, including digital-, cell- and gene therapies.

He is equally versed in life-cycle management and end-of-exclusivity transitions.

Work Experience

Immediately prior to joining Health Advances, Holger held Chief Commercial Officer positions at Biognosys AG, a leading mass spectrometry CRO with focus on proteome discoveries and Cell Medica, a cell therapy company, where Holger was responsible to launch one of the first cell therapy therapeutics into European markets. Holger also held the Chief Operating Officer position at Spiden an early stage medical device company using state-of-the-art detection technologies for vital medical indicator tracking. He previously worked in several senior commercial- and business development roles at Novartis Pharma, both at the global- and local affiliate level, while supporting development-stage and in-market projects across a wide area of therapeutic areas. Earlier, at Bain & Company, Holger consulted for leading pharmaceutical and Private Equity clients primarily on Due Diligences, M&A transitions, and post-merger integrations.

Education

Holger earned his MS degree in Chemistry from the Leibniz University and his PhD from the Swiss Federal Institute of Technology. He earned the CFA designation from the CFA Institute.

Connect With Me

We are always available for a conversation.

*